TILT-123 + pembrolizumab + pegylated liposomal doxorubicin
Phase 1/2RecruitingDevelopment Stage
Platinum-refractory Ovarian Carcinoma
Platinum-refractory Ovarian Carcinoma, Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Primary Peritoneal Carcinoma, Platinum-Sensitive Ovarian Cancer in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin, Platinum-Sensitive Fallopian Tube Carcinoma in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin, Platinum-Sensitive Primary Peritoneal Carcinoma in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin
May 17, 2022 → Aug 1, 2027
About TILT-123 + pembrolizumab + pegylated liposomal doxorubicin
TILT-123 + pembrolizumab + pegylated liposomal doxorubicin is a phase 1/2 stage product being developed by Merck for Platinum-refractory Ovarian Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05271318. Target conditions include Platinum-refractory Ovarian Carcinoma, Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05271318 | Phase 1/2 | Recruiting |
Competing Products
1 competing product in Platinum-refractory Ovarian Carcinoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Nivolumab Injection | Bristol Myers Squibb | Phase 2 | 51 |